Contemporary adjuvant polymethyl methacrylate cementation optimally limits recurrence in primary giant cell tumor of bone patients compared to bone grafting: a systematic review and meta-analysis

Dongqing Zuo†, Longpo Zheng†, Wei Sun, Dong Fu, Yingqi Hua* and Zhengdong Cai*

Abstract

Background: Reports of recurrence following restructuring of primary giant cell tumor (GCT) defects using polymethyl methacrylate (PMMA) bone cementation or allogeneic bone graft with and without adjuvants for intralesional curettage vary widely. Systematic review and meta-analysis were conducted to investigate efficacy of PMMA bone cementation and allogeneic bone grafting following intralesional curettage for GCT.

Methods: Medline, EMBASE, Google Scholar, and Cochrane databases were searched for studies reporting GCT of bone treatment with PMMA cementation and/or bone grafting with or without adjuvant therapy following intralesional curettage of primary GCTs. Pooled risk ratios and 95% confidence intervals (CIs) for local recurrence risks were calculated by fixed-effects methods.

Results: Of 1,690 relevant titles, 6 eligible studies (1,293 patients) spanning March 2008 to December 2011 were identified in published data. Treatment outcomes of PMMA-only (n = 374), bone graft-only (n = 436), PMMA with or without adjuvant (PMMA + adjuvant; n = 594), and bone graft filling with or without adjuvant (bone graft + adjuvant; n = 699) were compared. Bone graft-only patients exhibited higher recurrence rates than PMMA-treated patients (RR 2.09, 95% CI (1.64, 2.66), Overall effect: Z = 6.00; P <0.001), and bone graft + adjuvant patients exhibited higher recurrence rates than PMMA + adjuvant patients (RR 1.66, 95% CI (1.21, 2.28), Overall effect: Z = 3.15, P = 0.002).

Conclusions: Local recurrence was minimal in PMMA cementation patients, suggesting that PMMA is preferable for routine clinical restructuring in eligible GCT patients. Relationships between tumor characteristics, other modern adjuvants, and recurrence require further exploration.

Keywords: Giant cell tumors, Recurrence, Polymethyl methacrylate, Cementation, Bone grafting

Background

Giant cell tumors (GCTs) of bone are primary bone tumors of mesenchymal origin that commonly present as localized osteolytic lesions in the epiphysioendosteal region of long bones, though these tumors also occur with relatively lower frequency in other bone monostotic processes [1]. GCTs account for up to 20% of all primary skeletal neoplasms [1] and 5% of all adult primary bone tumors [2]. Recurrence reports in patient subpopulations vary, ranging from 0% to 65% [2].

For benign to locally aggressive GCT tumors, recurrence is most common in local tissues due to narrow surgical margins [3]; however, 3.5% of GCT patients develop remote benign or metastatic lesions [4-6], with malignancy variably reported in ≤30% of cases [7]. Diverse presentations, diagnostic methods, and treatment methodologies may contribute to discrepancies between reports [7,8]. Since the relatively recent decline of affected limb
amputation as a preferred treatment, contemporary clinical course and proper treatment selection have become more challenging [9]. Though modern curettage with local adjuvant or en bloc excision with prosthetic reconstruction are widely accepted treatment strategies for GCT of bone, consistently reported to reduce recurrence compared to wide excision [10-17], there is no consensus for optimal surgical curettage methodology, including fillers and adjuvants, to limit recurrence.

In routine intralesional curettage for GCTs of bone, adjuvants, such as the thermal adjuvant polymethyl methacrylate (PMMA) and chemical adjuvant phenol, have been recommended to reduce local recurrence following intralesional surgery, resulting in disease-free survival rates as high as 85% [2]. PMMA cementation treatment after curettage immediately stabilizes the affected limb and releases heat during polymerization that may kill remaining tumor cells [18,19], achieving recurrence rates ranging from 12 to 65.2% in various reports [13,20]. For lesions near the articulating surface, subchondral allogeneic bone grafting is also a widely accepted alternative for filling voids during intralesional curettage either with or without additional adjuvants, with recurrence rates comparable to PMMA treatment [2].

Despite the prevalence of studies concerning GCT and its recurrence, little conclusive data and no widely accepted consensus for optimal surgical management and adjuvant selection for GCT of bone are available. The current study investigates the efficacy of PMMA bone cementation and allogeneic bone grafting following intralesional curettage for surgical management of GCT of bone through a systematic review and meta-analysis, thus providing evidence for clinical treatment selection.

Methods
Study design
A systematic literature search was performed to identify cohort studies assessing efficacy and recurrence of primary GCT following intralesional curettage treatment with only PMMA bone cementation (PMMA-only), only allogeneic bone grafting (bone graft-only), PMMA bone cementation with or without adjuvant (PPMA + adjuvant), and allogeneic bone grafting with or without adjuvant (bone graft + adjuvant). Results were systematically analyzed to determine the relationship between treatment methods and recurrence rates in PMMA-treated and bone graft-treated patients.

Inclusion and exclusion criteria
Studies were included that reported information pertaining to efficacy and recurrence of GCT of bone following treatment with PMMA bone cementation or allogeneic bone grafting with or without other adjuvants. All included studies (1) contained patients who underwent intralesional curettage for treatment of pathologically verified primary GCTs; (2) reported void filling with either PMMA or allogeneic bone graft; (3) reported recurrence rates following intralesional curettage with ≥2 treatment groups for efficacy assessments; and (4) reported a ≥3 year follow-up period. All included studies were also (5) published or previously translated into in the English language. Studies that (1) did not include a retrospective control group or (2) contained patient cohorts sized ≤30 patients for any group were excluded.

Database search terms
Electronic searches were performed using the electronic databases provided by Google Scholar (1966 to September 2012), Medline (1966 to September 2012), EMBASE (1974 to September 2012), and the Cochrane Controlled Trial Register (Cochrane library 2012). Two independent researchers conducted literature searches using the search keywords ‘bone cement’, ‘PMMA’, ‘polymethyl methacrylate’, ‘bone graft’, ‘giant cell tumor of bone’, and ‘recurrence’ with various combinations of the operators ‘AND’, ‘NOT’, and ‘OR’.

Quality assessment
Eligible studies were evaluated for inclusion by two independent reviewers (Zuo and Hua), and the level of agreement between reviewers was recorded. Inclusion of resultant titles was determined by screening of manual titles and abstracts, followed by full-text screening by the same reviewers. The quality of each study was assessed using the Methodological Index for Nonrandomized Studies (MINORs) scoring system [21] and the Newcastle Ottawa Quality Assessment Scale (NOQAS). These scales were used to allocate a maximum of nine points for quality of selection, comparability, exposure, and outcome of study participants. In the event of incomplete data, authors of potentially eligible studies were contacted to obtain relevant unpublished data.

Outcome measurement
Local recurrence was the primary endpoint for analysis. Recurrence was defined as radiological and pathological evidence of local disease recurrence necessitating further surgical intervention.

Statistical analysis
All data were analyzed using RevMan v.5.1 software (Cochrane Collaboration, Copenhagen, Denmark). Risk ratio (RR) and 95% confidence intervals (CIs) were reported. Heterogeneity among studies was assessed using Cochrane’s Q test with a P value equal to 0.1. An I-squared (variability) statistic is the percentage of total variation across studies due to heterogeneity. A random effects model was used for heterogeneous data; otherwise, a fixed effect
model was used. Meta-analysis of pooled risk ratios was performed. \( P \) values less than 0.05 were considered statistically significant (\( P < 0.05 \)).

Result

Literature search

Initial electronic database searches yielded 1,690 relevant titles, of which 1,671 were excluded due to failure to meet the inclusion criteria. The remaining 19 articles were subjected to full-text review, resulting in exclusion of 8 additional articles due to failure to meet the inclusion criteria, most commonly due to inappropriate comparison methods. Additionally, two articles [10,17] were excluded due to insufficient primary GCT data. Notably, in both cases, original data was not able to be obtained from the corresponding authors. Furthermore, although three studies [22-24] included in the meta-analysis conducted by Liu et al. [25] met the inclusion criteria, these studies were excluded due to the relatively small number of included cases (35 PMMA-only and 20 bone graft-only). Study inclusion is detailed in Figure 1. Systematic review and meta-analysis were conducted using the remaining six included studies [2,11,12,14,15,20].

Study characteristics and quality assessment

In these 6 included retrospective cohort studies, data were reported for a total of 1,293 patients with primary GCTs of bone treated with either intralesional curettage or other resection methodologies. Median follow-up times for each study ranged from 60 to 108 months. Publication dates ranged from March 2008 to December 2011. Quality assessments revealed average NOQAS scores from the two reviewers of 7.4 and 7.0, indicating that all six included studies were of moderate quality.

Heterogeneity of studies

Variability (\( I^2 \)-squared) in the results of the four studies used to compare PMMA-only and bone graft-only patients demonstrated a true difference in treatment effect of 0%, indicating no heterogeneity. In all six studies used to compare PPMA + adjuvant and bone graft + adjuvant patients, \( I^2 \)-squared values were 56%, indicating relatively high heterogeneity. Thus, a random effects model was employed to adjust for heterogeneity prior to comparison of PPMA + adjuvant and bone graft + adjuvant patients.

Local recurrence

Complete data for recurrence was available in all included studies, and all six studies were included in analysis of local recurrence. Local recurrence rates differed significantly between PMMA-only patients and bone graft-only patients, with bone graft-only patients exhibiting significantly higher recurrence rates than PMMA-only patients (\( RR = 2.09, 95\% \ CI (1.64, 2.66), \) Overall effect: \( Z = 6.00; P <0.001; \) Figure 2). Local recurrence rates also differed between PPMA + adjuvant patients and bone graft + adjuvant patients. Bone graft + adjuvant patients also demonstrated higher levels of recurrence compared to PPMA + adjuvant patients (\( RR = 1.87, 95\% \ CI (1.55, 3.55), \) Test for overall effect: \( Z = 6.25; P <0.001; \) Figure 3).

Discussion and conclusions

In order to provide an accurate and contemporary analysis of GCT of bone treatments, the current meta-analysis was conducted of six methodologically sound studies, encompassing 1,293 GCT patients. Included patients were treated with intralesional curettage followed by PMMA cementation or allogeneic bone grafting, with results clearly indicating that PMMA cementation more optimally reduces recurrence risk in these patients. Despite extensive recent investigations of the relationships between adjuvant use and treatment efficacy, recurrence, and GCT of bone aggression, no consensus for proper treatment has been widely accepted. Thus, the current study provides novel and compelling evidence supporting preferential use of PMMA cementation in contemporary clinical intralesional curettage for GCT of bone.

PMMA treatment was administered to 594 patients, and the remaining 699 patients underwent no PMMA treatment. Among the total 1,293 patients, 436 patients were treated only with intralesional curettage and bone graft, and 373 patients were treated only with intralesional curettage and PMMA cementation.
multicenter retrospective study of sarcoma in 294 Scandinavian patients at 13 centers followed for a median of 5 years, Kivioja et al. [15] reported that PMMA cementation significantly reduced local recurrence rates following intralesional curettage, supporting widespread preferential use of PMMA treatments. Similar results were reported in a 384-patient, multicenter study conducted by Becker et al. [20], wherein 22% of GCT patients treated with PMMA and 49% of GCT patients treated with bone graft exhibited local recurrence within 63 months, evidence that further supports the use of PMMA treatments. Conversely, Liu et al. [25] conducted a systematic review and meta-analysis of 80 intralesional curettage patients with GCT of the distal radius, reporting that PMMA

| Study           | Publication date (year) | Follow-up (months) | Patient no. | Surgical treatment groups | Patient | Recurrence rate | Recurrence (n) |
|-----------------|-------------------------|--------------------|-------------|---------------------------|---------|-----------------|----------------|
| Becker et al. [20]| 2008                   | 63                | 384         | Total cohort              | 78/384  | 2.00%           | 1              |
|                 |                         |                   | 103/384     | curettage (bone graft)    | 49.00%  | 56              |
|                 |                         |                   | 102/384     | curettage + PMMA          | 22.00%  | 23              |
|                 |                         |                   | 74/384      | curettage + PMMA + phenol | 27.00%  | 20              |
|                 |                         |                   | 27/384      | curettage + toxic(bone graft) | 15.00%  | 4               |
| Errani et al. [11]| 2010                  | 91                | 349         | Total cohort              | 149/349 | 12.00%          | 18             |
|                 |                         |                   | 136/349     | Curettage + burr + phenol | 17.60%  | 24              |
|                 |                         |                   | 64/349      | Curettage + burr + phenol + PMMA | 12.50%  | 8               |
| Kivioja et al. [15]| 2008                  | 60 months         | 294         | Total cohort              | 92/294  | 12.00%          | 11             |
|                 |                         |                   | 47/294      | curettage                | 51.00%  | 24              |
|                 |                         |                   | 147/294     | curettage + PMMA         | 22.00%  | 32              |
| Klenke et al. [2]| 2010                   | 108 months        | 118         | Total cohort              | UN      | 5.00%           | unknown        |
|                 |                         |                   | 22/118      | curettage + burr          | 32.00%  | 7               |
|                 |                         |                   | 32/118      | curettage + burr + phenol | 34.00%  | 11              |
|                 |                         |                   | 41/118      | curettage + burr + phenol + PMMA | 15.00%  | 6               |
| Gaston et al. [12]| 2011                  | 76.5 months       | 330         | Total cohort              | 246/330 | 28.70%          | 67             |
|                 |                         |                   | 84/330      | curettage + PMMA         | 14.30%  | 12              |
| Jamshidi et al. [14]| 2008                 | 74 months         | 168         | Total cohort              | 40/168  | 42.50%          | 17             |
|                 |                         |                   | 40/168      | curettage + cement        | 30.00%  | 12              |
|                 |                         |                   | 46/168      | curettage + burr + bone   | 21.70%  | 10              |
|                 |                         |                   | 42/168      | curettage + burr + cement | 16.70%  | 7               |
| Harness et al. [22]| 2004                  | 72 months         | 31          | Total cohort              | 5/31    | 40.00%          | 2              |
|                 |                         |                   | 26/31       | curettage + PMMA         | 42.00%  | 11              |
| Ozalp et al. [23]| 2006                   | 80 months         | 8           | Total cohort              | 6/8     | 50.00%          | 3              |
|                 |                         |                   | 2/8         | curettage + PMMA         | 50.00%  | 1               |
| Sheth et al. [24]| 1995                   | 108 months        | 16          | Total cohort              | 9/16    | 33.00%          | 3              |
|                 |                         |                   | 7/16        | curettage + PMMA         | 28.50%  | 2               |
cementation was not an effective adjuvant compared with bone graft, with PMMA treatments exhibiting both higher rates of local recurrence and metastatic events. These discrepancies may be due to methodological differences as well as the fast-paced changes in routine surgical practices over the last several decades, indicating that contemporary evaluation of these methods is required. Thus, a consensus pertaining to treatment standards for GCT has not yet been reached, though the current study provides powerful, contemporary evidence to support preferential PMMA adjuvant use in modern clinical settings.

Without the use of adjuvants, reoccurrence rates following intralesional curettage as high as 35 to 49% have been reported [2,20]. Increases in available adjuvant types and numbers in recent years have, however, further complicated the treatment selection process for GCT patients, though few studies have conducted systematic comparisons of the cytotoxic characteristics of specific adjuvant formulations [26]. As a result, the vast selection of clinically-approved adjuvants may be overwhelming for many clinicians, resulting in default use of suboptimal older methods due to subjective comfort levels rather than clinical viability [26]. Several reports have reported dramatic decreases in recurrence rates in patients treated with PMMA, PMMA with phenol, or phenol with other chemical adjuvants (22%, 27%, and 15% recurrence, respectively) [3,16,27,28]. Niu et al. [16] reported that extended curettage with combined high speed burring, bone graft, and PMMA cementation resulted in an extremely low recurrence rate of 3.3%, though numerous other studies refute these findings and provide conflicting results [14,17,25,29,30]. Algawahmed et al. [29] conducted a systematic review and meta-analysis of 387 GCT patients, demonstrating that meticulous surgical techniques, including high-speed burring, are paramount to reducing GCT recurrence rates. Furthermore, these findings and those of the current study further indicated that local adjuvants, such as PMMA, were not associated with recurrence. Similarly, a meta-analysis of 139 GCT patients with symptoms in the distal radius conducted by Liu et al. [25] suggested that tumor recurrence in patients treated with PMMA did not differ significantly from that observed in patients treated with bone grafting.

In the current meta-analysis, only four articles were used to assess PMMA-only and bone-graft only treatments [12,14,15,20], while six articles were used to assess PMMA and bone grafts applied either with or without other adjuvants following intralesional curettage [2,11,12,14,15,20]. The current findings used pooled data to reveal significant differences in both comparison groups, with primary GCTs patients treated with PMMA cementation following intralesional curettage exhibiting relatively lower recurrence rates than patients treated with bone grafts following intralesional curettage. It has been hypothesized that the additional heat produced by the exothermic reaction of in situ PMMA polymerization may contribute to removal of remaining tumor cells in the curetted cavity of GCT lesions [15], thereby reducing recurrence. Similarly, it has been suggested that abnormal mitosis, increased mitotic rate (>10 mm2), and permeation of vascular channels may increase tumor aggressiveness and recurrence rates [7], thereby making adjuvant treatment with PMMA less useful due to the larger distribution of tumor cells in local tissues.

While these compounding factors may, in part, explain the controversial findings reported by different studies, further clinical, radiologic, and histologic investigation...
will be required to assess the potential relationships between adjuvant treatments and the myriad of contemporary compounding factors. Based on both previous findings and current experience, it is hypothetically possible that tumor volume may also influence recurrence of primary GCTs. Logically, both PMMA cementation and bone graft treatments are likely to be less effective following intralesional curettage in cases of very small tumors, which are more difficult to excise and fill [31]. Because this raises the likelihood that some tumor cells will elude the hypothetical thermal effects of PMMA, such adjuvant treatment is likely to be less effective in GCTs with very small volumes. This volume-effect hypothesis, however, will require further clinical exploration.

Despite the relatively large number of patients studied, the limitations of meta-analyses containing only a small number of studies must be considered. Due to the relative scarcity of both the disease and relevant, reputable randomized control trials, other meta-analyses in this field have also been conducted using very small groups of articles, including the studies by Algawhmed et al. [29] and Liu et al. [25]. The largest number of included patients were contributed by the report of Becker et al. [20], consisting of 384 patients. These patients included 256 primary GCT cases and 128 recurrent GCT cases. Notably, failure to distinguish between primary and recurrent GCT cases in the Becker et al. study is a potentially confounding factor in the current study. The difference between local recurrence rates between primary and recurrent tumors was found to be negligible in this study (21.9% versus 23.4%), and the other two studies that included both primary and recurrent GCT cases [10,17] were excluded due to significant differences between primary local recurrence and overall recurrent rates (33.5% versus 20% and 35% versus 18%, respectively). Furthermore, adjuvants applied along with PMMA and bone graft treatments following curettage were not distinguished, and future study will be required to assess whether different adjuvant combinations may alter outcomes.

It is important to note that when only local recurrence outcomes are assessed, as in the current study, the effects of potentially important parameters may be overlooked, such as metastatic rate, abnormal mitoses, and related major complication rates. Szalay et al. [32] and Gaston et al. [12] suggested that joint cartilaginous degeneration may occur following PMMA cementation in joint arthroplasty. Similarly, Gaston et al. [12] evaluated the rate of joint replacement for patients with GCTs, revealing that patients treated with PMMA evidenced significantly higher rates of joint replacement. While metastasis in GCT patients is rare [33,34], up to 3% of metastatic GCT occurrences are found in pulmonary tissues [11,35]. Notably, only three studies [2,11,12] included in the current analysis provided discrepant results relating to metastasis and function. While this data is obviously insufficient to conduct a current analysis of these functional results, this provides an interesting topic for further study.

The current study of pooled data from 1,293 primary GCTs cases in six studies in contemporary medical literature, revealed that PMMA cementation following intralesional curettage produced lower recurrence rates compared to recurrence rates in patients treated with bone grafting. Recent advancements in GCT of bone treatment methodologies have produced numerous compounding factors that must be considered in order to achieve better outcomes in these patients, making modern adjuvant formulations and surgical methodologies critical aspects of treatment selection. Thus, this study provides critically needed systematic, evidence-based evidence indicating that PMMA is a superior treatment for the majority of GCT of bone cases treated in routine clinical practice. To better evaluate new and improved adjuvant treatments, however, additional multicenter studies with sufficient and comprehensive data regarding tumor characteristics will be required.

Abbreviations
GCT: Giant cell tumor; MINORS: Methodological Index for Nonrandomized Studies; NOQAS: Newcastle Ottawa Quality Assessment Scale; RR: Risk ratio.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
ZD, ZL carried out the studies, participated in collecting data, and drafted the manuscript. SW, FD performed the statistical analysis and participated in its design. HY, CZ helped to draft the manuscript. All authors read and approved the final manuscript.

Received: 13 December 2012 Accepted: 30 June 2013
Published: 16 July 2013

References
1. Purohit S, Pardiwala DN: Imaging of giant cell tumor of bone. Indian J Orthop 2007, 41:91–96.
2. Kienke FM, Wenger DE, Inwards CY, Rose PS, Sim FH: Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 2011, 469:591–599.
3. Campenacci M, Baldini N, Boriani S, Suardese A: Giant-cell tumor of bone. J Bone Joint Surg Am 1987, 69:106–114.
4. Goldenberg RR, Campbell CJ, Bonfiglio M: Giant-cell tumor of bone: an analysis of two hundred and eighteen cases. J Bone Joint Surg Am 1970, 52:619–664.
5. Sneath N, Ayala AG, Carraccio CH, Murray J, Raymond AK: Giant cell tumor of bone: a cytologic study of 24 cases. Diagn Cytopathol 1985, 1:111–117.
6. Szokolowski WM, Schiller AL: Cytologic diagnosis of giant cell tumor of bone metastatic to lung: a case report. Acta Cytol 1979, 23:460–464.
7. Hutter RV, Worcester JN Jr, Francis KC, FFJS FW: Benign and malignant giant cell tumors of bone: a clinicopathological analysis of the natural history of the disease. Cancer 1962, 15:653–690.
8. Sanerkin NG: Malignancy, aggressiveness, and recurrence in giant cell tumor of bone. Cancer 1980, 46:1641–1649.
9. McCarthy EF: Giant-cell tumor of bone: an historical perspective. Clin Orthop Relat Res 1980, 153:14–25.
10. Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, Hardes J, Goehler G: Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 2008, 134:969–978.
11. Errani C, Ruggieri P, Asencio MA, Toscano A, Colangeli S, Rimondi E, Rossi G, Longhi A, Mercuri M: Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev 2010, 36:1–7.
12. Gaston CL, Bhumbra R, Watanuki M, Abudu AT, Carter SR, Jeys JM, Tillman RM, Grimer RJ: Does the addition of cement improve the rate of local recurrence after curettage of giant cell tumors in bone? J Bone Joint Surg Br 2011, 93:1665–1669.
13. Gaston CL, Slavin J, Henderson M, Choong PF: Epithelioid angiomyolipoma with skeletal and pulmonary metastasis on 8 year follow-up. Pathology 2010, 42:591–594.
14. Jamshidi K, Sanni S, Modares-Nejad H, Jahaniouz A: Local recurrence in giant cell tumor of bone: comparative study of two methods of surgical approach. J Res Med Sci 2008, 13:223–229.
15. Kviola AH, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer HC, Jorgensen PH, Bergh P, Folleras G: Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian sarcoma group study of 294 patients followed for a median time of 5 years. Acta Orthop 2008, 79:86–93.
16. Niu X, Zhang Q, Hao L, Ding Y, Li Y, Xu H, Liu W: Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution. J Bone Joint Surg Am 2012, 94:461–467.
17. Turcotte RE, Wunder JS, Iser MH, Bell RS, Schachar N, Masri BA, Moreau G, Davis AM: Giant cell tumor of long bone: a Canadian sarcoma group study. Clin Orthop Relat Res 2002, 397:248–258.
18. Frassica FJ, Gorski JP, Pritchard DJ, Sim FH, Chao EY: A comparative analysis of subchondral replacement with polymethylmethacrylate or autogenous bone grafts in dogs. Clin Orthop Relat Res 1993, 293:378–390.
19. Nelson D, Barker M, Hamlin B: Thermal effects of acrylic cementation at bone tumour sites. Int J Hyperthermia 1997, 13:287–306.
20. Becker WT, Dohle J, Bernd L, Braun A, Cserhati A, Enderle A, Hovy L, Matejovska Z, Szendro M, Treib R, Turn P-U: Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 2008, 90:1060–1067.
21. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J: Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003, 73:712–716.
22. Harness NG, Mankin HJ: Giant-cell tumor of the distal forearm. J Hand Surg Am 2004, 29:188–193.
23. Ozalp T, Yercan H, Okcu G, Ozdemir O, Coskunol E: Giant cell tumor at the wrist: a review of 23 cases. Acta Orthop Traumatol Turc 2006, 40:144–150.
24. Sheth DS, Healey JH, Sobel M, Lane JM, Marcove RC: Giant cell tumor of the distal radius. J Hand Surg Am 1995, 20:432–440.
25. Liu YP, Li RH, Sun BH: Which treatment is the best for giant cell tumors of the distal radius? A meta analysis. Chin Orthop Relat Res 2012, 470:2886–2894.
26. Gortzak Y, Kandel R, Deheshi B, Werier J, Turcotte RE, Ferguson PC, Wunder JS: The efficacy of chemical adjuvants on giant-cell tumour of bone: an in vitro study. J Bone Joint Surg Br 2010, 92:1475–1479.
27. Chanchairujira K, Jiranantanakorn T, Phimolsarnti R, Asavamongkolkul A, Waikul S: Factors of local recurrence of giant cell tumor of long bone after treatment: plain radiographs, pathology and surgical procedures. J Med Assoc Thai 2011, 94:1230–1237.
28. van der Heijden L, van de Sande MA, Dijkstra PD: Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones. Acta Orthop 2012, 83:401–405.
29. Algawahmed H, Turcotte R, Farrokhyar F, Ghert M: High-speed burring with and without the use of surgical adjuvants in the intralesional management of giant cell tumor of bone: a systematic review and meta-analysis. Sarcoma 2010, doi:10.1155/2010/586090.
30. O’Donnell RJ, Springfield DS, Motwani HK, Ready JE, Gebhardt MC, Mankin HJ: Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am 1994, 76:1827–1833.
31. Yanagisawa M, Okada K, Tajiyo T, Torigoe T, Kawai A, Nishida J: A clinicopathological study of giant cell tumor of small bones. Ups J Med Sci 2011, 116:265–268.
32. Salay K, Antal I, Kiss J, Szendro M: Comparison of the degenerative changes in weight-bearing joints following cementing or grafting techniques in giant cell tumour patients: medium-term results. Br Orthop 2006, 30:505–509.
33. Gong L, Liu W, Sun X, Sajdik C, Tian X, Niu X, Huang X: Histological and clinical characteristics of malignant giant cell tumor of bone. Virchows Arch 2012, 460:327–334.
34. Rock MG, Pritchard DJ, Unni KK: Metastases from histologically benign giant-cell tumor of bone. J Bone Joint Surg Am 1984, 66:269–274.
35. Miller LJ, Blank A, Yin SM, McNickle A, Gray R, Geltis S: A case of recurrent giant cell tumor of bone with malignant transformation and benign pulmonary metastases. Diagn Pathol 2010, 5:62.